WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russo-Neustadt, A.
Right arrow Articles by Cotman, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russo-Neustadt, A.
Right arrow Articles by Cotman, C. W.

 Previous Article  |  Next Article 

Volume 17, Number 14, Issue of July 15, 1997 pp. 5573-5580
Copyright ©1997 Society for Neuroscience

Adrenergic Receptors in Alzheimer's Disease Brain: Selective Increases in the Cerebella of Aggressive Patients

Amelia Russo-Neustadt and Carl W. Cotman

Institute for Brain Aging and Dementia, University of California, Irvine, California 92697-4540

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

In this study, the distribution and concentration of beta 1, beta 2, and alpha 2 adrenergic receptors were examined in the frontal cortex, hypothalamus, and cerebellum of Alzheimer's disease (AD) and age-matched control human brains by receptor autoradiography. The purpose of this study was to detect changes in adrenergic receptor concentrations in key areas of the brain known to affect behavior. For these studies, [125I]iodopindolol ([125I]IPIN) was used to visualize total beta  adrenergic sites (with ICI-89,406 and ICI-118,551 as subtype-selective antagonists to visualize beta 2 and beta 1 receptors, respectively). [3H]UK-14,304 was used to localize the alpha 2 sites. Essentially no significant difference in adrenergic receptor concentration was found between total AD cases taken together and control patients. It was found, however, that there were important distinctions within the AD group when cases were subdivided according to the presence or absence of aggression, agitation, and disruptive behavior. Aggressive AD patients had markedly increased (by ~70%) concentrations of alpha 2 receptors in the cerebellar cortex compared with nonaggressive patients with similar levels of cognitive deficit. The levels of cerebellar alpha 2 receptors in aggressive AD patients were slightly above the healthy elderly controls, suggesting that these receptors are preserved and perhaps increased in this subgroup of AD. beta 1 And beta 2 adrenergic receptors of the cerebellar cortex showed smaller but significant (~25%) increases in concentration in aggressive AD subjects versus both nonaggressive AD patients and controls. No significant differences were found in adrenergic receptor concentrations within the frontal cortex or hypothalamus. These results point out the importance of distinguishing behavioral subgroups of AD when looking for specific neurochemical changes. These autoradiographic results may reflect the importance of the cerebellum in behavioral control.

Key words: autoradiography; dementia; aggression; behavioral disorder; receptor localization; frontal cortex; hypothalamus

INTRODUCTION

Much evidence exists that the adrenergic system has an important role in normal CNS function as well as in brain disease. It has been proposed that the main function of the locus ceruleus (LC) and its projections is to determine the brain's global orientation concerning events in the external world and within the viscera (Cooper et al., 1991). Central norepinephrine (NE) neurons are suggested to have a role in learning and memory, reinforcement, sleep-wake cycle regulation, affective psychoses, and the regulation of aggression. Drugs effective in the treatment of neuropsychiatric illness, including depression and aggressive or disruptive behavior, are active on adrenergic receptors.

Several studies have been completed to investigate changes in neurotransmitters or their receptors in Alzheimer's disease (AD) so that the neurological deficits in AD can be better understood and more effective treatments can be developed. The LC, the predominant source of noradrenergic projection neurons in the brain, is significantly damaged in Alzheimer's disease (Ishino and Otsuki, 1975). Although adrenergic receptors in these projection areas of AD brains have been studied, and some abnormalities have been observed (Kalaria et al., 1989a; Meana et al., 1992), there have been variable results. A possible reason for a lack of significant changes in some receptor studies is the heterogeneity among AD cases. Much evidence exists for subgroups within the AD population. For example, in addition to variations in the severity of the cognitive deficits in AD patients, there are various behavioral abnormalities that appear to be present in subgroups of AD patients (Reisberg et al., 1987; Mega et al., 1996). These behavioral symptoms include apathy, agitation/aggression, dysphoria, and aberrant motor behaviors.

This study has sought to investigate changes in adrenergic receptor concentrations in key areas of the brain known to affect behavior. Limbic regions of the brain, such as the frontal neocortex and hypothalamus, are projection regions of the LC known to contain significant levels of NE and adrenergic receptors, and to function in the modulation of behavior (Weiger and Bear, 1988). The cerebellar cortex is another LC projection area that has been shown to participate in behavioral control, in addition to motor control (Schmahmann, 1991). Adrenergic receptor concentration and distribution were investigated in these brain regions of AD patients and normal elderly controls by way of receptor autoradiography.

MATERIALS AND METHODS

Patient selection and tissue preparation Brain tissue was obtained from the University of California, Irvine, Alzheimer's Disease Research Center Repository Core (Table 1). Tissue was sectioned into 1-cm-thick coronal slices and frozen on dry ice at autopsy with a postmortem interval of 2-14 hr and stored at -80°C until processed for autoradiography. All tissue was handled in the same manner, and all cases were examined neuropathologically for definitive AD diagnosis. Controls were matched to experimental tissue for age and postmortem delay. Control sections were mounted side by side with AD sections on the same slide. Brain areas studied included the frontal neocortex (examining separately the dorsolateral prefrontal and orbitofrontal cortices; Brodmann areas 10 and 11, respectively), the hypothalamus (ventromedial, dorsomedial, posterior, and lateral nuclei), and the cerebellar cortex (from the cerebellar hemispheres).

Table 1. Sources of brain tissue

Case Source Age Sex PMI MMSE Cause of death Medications
Ag-AD
   1 ADRC clinic 88 F 14 8 Cardiac arrest Dyazide, haloperidol, ibuprofen, multivitamins
   2 ADRC clinic 85 M 12 20, 11 Cardiopulmonary arrest Loxapine
   3 ADRC clinic 90 M 8 13 Myocardial infarction Aspirin
   4 ADRC clinic 73 F 2 18 Cardiopulmonary arrest Furosemide, potassium, digoxin, enalapril, nifedipine
Clorazepic acid, trazodone, tylenol, coumadin
   5 TRCP 70 M 2.5 18 Cardiopulmonary arrest Nortriptyline
   6 ADRC clinic 86 F 2.25 21, 19 Respiratory failure Hydrochlorothiazide, furosemide, naproxen, tacrine
  meclizine, digoxin, diclofenac sodium, amitriptyline
   7 ADRC clinic 74 M 6.5 23 Cardiac arrest Bumetanide, colchicine
   8 ADRC clinic 73 F 9.5 2 Respiratory failure Digoxin, haloperidol, ranitidine, omperazole, estrogen, prednisone, theophylline
Controls
   9 TRCP 89 M 9 N/A Cardiac arrest None
  10 TRCP 83 M 7.5 N/A Aspiration pneumonia, cancer Vicodin, morphine, triazolam
  11 TRCP 71 F 4 N/A Chronic pulmonary disease Theophylline, metaproterenol, iron, prednisone
  12 TRCP 65 M 4.5 N/A Cardiac arrest Captopril, furosemide, nitroglycerine, iron, fluoxetine, diltiazem, coumadin, aspirin, albuterol, ipra-tropium bromide, triamcinolone acetonide
  13 TRCP 81 F 6 N/A Cardiac arrest Digoxin, prednisone, albuterol, trazodone
  14 TRCP 77 M 6.5 N/A Cardiac arrest Thyroid hormone
  15 TRCP 76 F 4.5 N/A Myocardial infarction Prednisone, lorazepam, theophylline
nAg-AD
  16 ADRC clinic 79 M 12 23, 20 Pneumonia Dihydroergotamine mesylate, aspirin, florinef, salt tablets, piroxicam
  17 ADRC clinic 73 M 8 9 Cardiopulmonary arrest Carbidopa, amitriptyline, vitamin E, selegeline
  18 ADRC clinic 72 F 12 5 Brain embolism Phenytoin, estrogen
  19 ADRC clinic 73 M 6 19, 6 Cardiac arrest Ergometrinine, aspirin, imipramine
  20 ADRC clinic 77 M 6.5 19 Cardiac arrest Imipramine, cycloserine (study), quinidine
  21 ADRC clinic 90 F 8.5 18 Cardiac arrest Captopril, aspirin, multivitamins
  22 ADRC clinic 80 F 3 19 Stroke Nitrofurantoin, carbidopa, oxybutynin, warfarin, Atenolol, triamterine
  23 ADRC clinic 95 F 9.5 14 Cardiopulmonary arrest None
Ag-AD, Aggressive Alzheimer's disease subgroup; nAg-AD, non-aggressive AD subgroup; ADRC, Alzheimer's Disease Research Center; TRCP, Tissue Repository Consent Program; MMSE, Mini Mental State Exam scores (two scores reflect two evaluations in consecutive years); PMI, postmortem interval (hours).

Autoradiography For autoradiographic experiments, the brain tissue was cryostat-sectioned at -15°C (12 µm for alpha 2 assays and 20 µm for beta ), thaw-mounted onto gelatin-subbed slides over ice, and stored at -20°C for up to 1 week until used in the assays. As described above, sections from the three patient groups were mounted on the same slide to minimize any interslide variability in conditions. Sections for assays were taken in triplicate, and repeats were randomized with respect to position on the slide (top or bottom) and cases with which they were paired.

alpha 2-adrenergic receptors. alpha 2-Adrenoceptors were labeled with the selective agonist [3H]bromoxidine ([3H]UK-14,304, 64.0 Ci/mmol, New England Nuclear, Boston, MA) according to the procedure of Pazos et al. (1988). After a 15 min preincubation at room temperature in Tris-HCl buffer (50 mM, pH 7.7) containing 0.1 mM MnCl2, slide-mounted, 12 µm tissue sections were incubated with 6 nM [3H]UK-14,304 for 90 min under the same conditions. After the incubation, sections were washed for 5 min in ice-cold buffer and dried in a cold air stream. Nonspecific binding was defined as that remaining in the presence of 10 mM phentolamine. Sections were exposed at 4°C for 8 weeks to tritium-sensitive film (Hyperfilm-3H, Amersham, Arlington Heights, IL) before development and analysis.

beta -Adrenergic receptors. The general procedure described by Rainbow et al. (1984) was used to determine the distribution of total beta -adrenergic receptor sites and of the beta 1 and beta 2 subtypes. Cryostat sections (20 µm thickness) were used for these experiments. Slides were placed horizontally on trays, and 1 ml of buffer containing [125I]iodopindolol ([125I]IPIN) was layered on the tissue. The slide-mounted tissue sections were incubated for 70 min with 200 pM [125I]IPIN in Tris-saline buffer to determine the distribution of total [125I]IPIN sites. In serial sections, 50 nM of the selective beta 2 receptor antagonist ICI-118,551 or 70 nM of the selective beta 1 receptor antagonist ICI-89,406 was included to visualize binding of [125I]IPIN to beta 1 and beta 2 subtypes, respectively. Nonspecific binding was determined from sections co-incubated in the presence of 100 mM isoproterenol, a nonselective agonist. Sections were then washed twice for 15 min each in the incubation buffer at 4°C, rinsed quickly in cold water to remove buffer salts, dried under a stream of cool air, and stored with desiccant at 4°C overnight to remove any remaining moisture.

To prepare autoradiographs, the incubated slides were loaded into cassettes and apposed to tritium-sensitive film (Hyperfilm-3H, Amersham) for 12-18 hr at room temperature before the film was developed.

Analysis of autoradiograms. Receptor densities as reflected in autoradiograms were analyzed by computer-assisted densitometry. The illuminated image of each autoradiograph was collected by a camera connected to an IBM computer with an MCID (St. Catherines, Ontario, Canada) image processing system. Autoradiographic images were calibrated relative to [125I]- or [3H]-labeled standards exposed together with the tissue to the film. Areas (7 × 0.2 mm2) were randomly selected from each cell layer or nucleus in each of three sections per case to determine silver grain density. Differences in [125I]IPIN or [3H]UK-14,304 binding between cases were determined by paired Student's t tests.

RESULTS

alpha 2-Adrenergic receptor binding

[3H]UK-14,304 binding to human brain tissue sections was saturable and of high affinity, with distributions and pharmacological competition profiles corresponding to alpha 2 receptors.

Cerebellum

In the human cerebellar cortex, high levels of alpha 2-adrenergic receptor binding were observed in both molecular and granule cell layers, with no labeling in the subcortical white matter (Fig. 1). Overall, the concentration of alpha 2 receptor labeling in the AD cases was quite variable compared with normal, healthy controls, and when averaged, appeared to be slightly lower, or essentially equal (difference nonsignificant; Fig. 2A). We next sought to investigate whether subdivision of the AD cases by a specific behavioral derangement would result in more homogeneity within each group. The AD cases examined were divided according to the presence or absence of agitated and aggressive behaviors during the patients' disease course. This was determined by reviewing the results of the California ADDTC Behavior Questionnaire (Mungas et al., 1993), a caregiver-completed, ordinally scaled instrument with 62 questions rating the frequency of a broad range of behaviors (including agitation, aggression, depression, insomnia, and psychosis) and 19 items rating the severity of emotional symptoms. For all cases examined, the questionnaire was administered by the same trained registered nurse. The aggressive AD cases were matched to AD patients with no history of aggression by degree of cognitive impairment, as determined by the Mini Mental State Exam (Folstein et al., 1975). Now with three patient groups examined, the alpha 2 receptor levels were strikingly highest in the agitated, aggressive subgroup of AD patients, with lowest levels seen in the nonagitated AD group (a 70% increase in agitated vs nonagitated subgroups) (Fig. 2B). Elderly control patients without AD diagnoses showed alpha 2 receptor concentrations slightly lower than those of the agitated AD subgroup (difference not statistically significant).
Fig. 1. Top. Pseudocolor images of alpha 2 adrenergic receptor distribution in human cerebellar cortex. A and B are photomicrographs of the autoradiographic distribution of [3H]UK-14,304 binding sites in the cerebella of nonaggressive and aggressive AD subjects, respectively. Note the higher level of alpha 2 receptor concentration in the granule cell and molecular layers of this cerebellar cortical section from an aggressive AD patient (B) compared with a patient from the nonaggressive AD subgroup (A). W, White matter; GCL, granule cell layer; ML, molecular layer. Approximate pseudocolor scale is in femtomoles/mg protein. Scale bar, 3 mm.   
Fig. 3. Bottom. beta  adrenergic receptor binding in cerebellar cortex. A, B, Pseudocolor images of total beta  adrenergic receptor distribution in human cerebellar cortex. A and B are photomicrographs of the autoradiographic distribution of [125I]IPIN binding sites in the cerebella of nonaggressive (A) and aggressive (B) AD subjects. C and D are histograms of receptor density (in femtomole/milligram protein) for the two subtypes of beta  adrenergic receptors. C shows the levels of beta 1 receptor binding in the different layers of the cerebellar cortex of two subgroups of AD patients (agitated and nonagitated) and normal elderly controls. Note the moderate but significant increases in beta 1 receptor concentration in the granule cell layer, Purkinje cell layer, and subcortical white matter of aggressive AD patients over both nonaggressive AD patients and controls. D Displays the levels of beta 2 adrenergic receptors in these groups. Significant increases in concentration for this beta 2 receptor subtype of agitated AD patients over both the nonagitated subgroup and the controls are detected in subcortical white matter only. W, White matter; GCL, granule cell layer; PCL, Purkinje cell layer; ML, molecular layer. Approximate pseudocolor scale is in femtomoles/mg protein. Scale bar, 3 mm.
[View Larger Version of this Image (118K GIF file)]

Fig. 2. alpha 2 receptor density in the cerebellar cortex. A, Density of alpha 2 adrenergic receptor ([3H]UK-14,304) binding in the cerebellar cortex of AD (all patients combined) and normal elderly controls. B, Density of alpha 2 adrenergic receptors in the cerebellar cortices of AD patients with (AD-Ag) and without (AD-nAg) a history of aggression and in normal age-matched controls. Note the lack of significant difference in receptor density when all AD patients are combined and the striking separation in receptor densities between the two subgroups of AD patients. The aggressive subgroup shows an ~70% increase in density over the nonagitated patients, whose level of alpha 2 receptor concentration is lower than that of controls. ML, Molecular layer; GCL, granule cell layer; * p < 0.005 (for difference between AD-Ag and AD-nAg).
[View Larger Version of this Image (33K GIF file)]

Frontal cortex

Highest levels of alpha 2-adrenergic receptor binding in the orbitofrontal cortex were observed in layer I, with intermediate levels in layer III, and relatively low levels in layers II and IV-VI. There was no labeling observed in the subcortical white matter. In the dorsolateral prefrontal cortex, highest binding levels were evident in layers I and III, with intermediate levels in layers V/VI, and low levels in layers II and IV. No significant differences were found in alpha 2-adrenergic receptor distribution or densities between AD patients and age-matched controls in either of these cortical areas, nor were differences observed between the agitated and nonagitated subgroups of AD patients. For illustrative purposes, the results from the orbitofrontal cortex are shown in Table 2 (the dorsolateral prefrontal cortex also showed no significant differences between the three groups).

Table 2. alpha 2-Adrenergic receptor concentration in the hypothalamus and orbitofrontal cortex

Hypothalamus
Nuclei n Ag n nAg n Control
  DM 5 263.10  ± 23.07 5 261.66  ± 19.53 0
  VM 4 290.04  ± 26.34 3 305.01  ± 24.15 1 249.6  ± 0.00
  LAT 10 363.93  ± 51.12 5 328.50  ± 26.01 3 360.81  ± 95.76
  POST 8 172.53  ± 27.75 4 120.75  ± 9.30 3 181.41  ± 30.06
Orbitofrontal cortex
Layer
 n
 Ag
 n
 nAg
 n
 Control
  I 4 630.45  ± 44.46 4 680.16  ± 89.76 4 775.20  ± 69.93
  III 4 472.44  ± 26.22 4 453.36  ± 40.59 4 488.25  ± 32.88
  IV 4 382.35  ± 24.78 4 390.99  ± 36.27 4 392.70  ± 30.15
  V-VI 4 358.95  ± 20.22 4 351.15  ± 28.14 4 362.25  ± 36.33
Densities of alpha 2-adrenergic receptors in orbitofrontal cortex and in nuclei of the hypothalamus of Alzheimer's disease patients with (AD-Ag) and without (AD-nAg) a history of aggression, and in normal age-matched controls, in femtomoles/mg protein ± SEM. No significant differences were found in receptor densities among the three groups of patients either in orbitofrontal (chosen for illustration) or dorsolateral prefrontal cortices or in the hypothalamus. DM, Dorsomedial nucleus; VM, ventromedial nucleus; LAT, lateral nucleus; POST, posterior nucleus.

Table 3. Densities of beta -adrenergic receptors in the nuclei of the hypothalamus and in layers of the orbitofrontal cortex

Hypothalamus---total beta -adrenergic receptors
Nuclei n Ag n nAg n Control
  DM 5 74.694  ± 9.922 5 50.066  ± 3.564 1 64.630  ± 0.00
  VM 4 62.200  ± 7.591 2 40.170  ± 2.420 2 64.255  ± 22.575
  LAT 9 47.023  ± 5.557 5 45.090  ± 11.795 3 55.027  ± 5.466
  POST 7 51.409  ± 5.182 5 39.882  ± 9.831 3 41.200  ± 1.511
Orbitofrontal cortex---beta 1-adrenergic receptors
Layers
 n
 Ag
 n
 nAg
 n
 Control
  I-II 4 22.312  ± 2.520 7 21.526  ± 1.791 4 14.442  ± 3.699
  III-IV 3 17.907  ± 1.611 7 16.410  ± 1.077 2 13.760  ± 4.720
  VI 4 18.703  ± 1.338 1 19.130  ± 1.486 1 17.640  ± 0.000
Data are expressed in femtomole/milligram ± SEM. No statistically significant differences were found among the patient groups examined in any layers of either orbitofrontal (chosen for illustration) or dorsolateral prefrontal cortex, or in the hypothalamus. DM, Dorsomedial nucleus; VM, ventromedial nucleus; LAT, lateral nucleus; POST, posterior nucleus.

Hypothalamus

The highest levels of alpha 2 receptor binding in the human hypothalamus were present in the lateral nucleus, with intermediate levels in the dorsomedial nucleus, and low levels in the ventromedial and posterior nuclei. Receptor binding densities in these four hypothalamic nuclei were compared between AD and control and between the two AD subgroups, and no significant differences were found in alpha 2 receptor concentrations (Table 2).

beta -Adrenergic receptor binding

Binding of [125I]IPIN to human brain tissue sections was of high affinity, saturable, and with a pharmacological competition profile corresponding to beta -adrenergic receptors. Displacement by the selective beta 1 antagonist ICI-89,406 or the selective beta 2 antagonist ICI-118,551 was used to define binding to the beta 2 and beta 1 receptors, respectively. All human brain regions examined contained both receptor subtypes, with the relative ratio of beta 1/beta 2 ranging from 70:30 in certain layers of the prefrontal cortex to 20:80 in the cerebellar cortex. In all regions, the sum of the densities of the two receptors was approximately equal to the total binding for [125I]IPIN.

Cerebellum

The overall ratio of beta 1- to beta 2-adrenergic receptor binding in this brain area was ~20:80. Highest levels of beta  receptors were observed in the granule and Purkinje cell layers, with low levels in the molecular layer, and intermediate levels over the subcortical white matter (Fig. 3). This agrees with beta -adrenergic autoradiographic distributions reported previously in human brain (Reznikoff et al., 1986). There were no significant differences in receptor densities in the cerebellar cortices of all AD patients taken together versus controls (data not shown). Cerebella of aggressive demented patients showed small but significant increases in total beta -adrenergic receptor density versus both healthy controls and nonaggressive AD patients (Fig. 3A,B). The beta 1 subtype showed small but significant increases in density in the granule cell layer and Purkinje layer as well as in white matter (Fig. 3C), whereas the beta 2 subtype showed significant increases in the subcortical white matter only (Fig. 3D). These results suggest that the observed beta -adrenergic receptor binding increases are specific to AD with aggression/agitation.

Because receptor concentration increases are evident in the white matter as well as in cerebellar cortical layers, it is possible that the receptors observed in this study may include beta -adrenergic receptors on cerebral microvessels and/or glia. Adrenergic receptors (primarily beta ), innervated by noradrenergic LC neurons, are known to exist in brain microvessels (Kobayashi et al., 1982; Kalaria et al., 1989c). In fact, beta 2 receptors in cerebral microvessel fractions from human brain have been found to be increased significantly in AD (Kalaria and Harik, 1989). Both normal and reactive astrocytes are known to express beta -adrenergic receptors in adult rat brain (Sutin and Shao, 1992). In the visual cortex of the adult cat, ~50% of cells expressing beta -adrenergic receptors have been shown to be astrocytes (Liu et al., 1992). This includes cells both within the cortical layers and within the subcortical white matter.

Frontal cortex

In the human orbitofrontal cortex, high levels of beta 1 receptors were observed in layers I and II, with low levels in layers III-V, and intermediate levels in layer VI. There was no labeling in subcortical white matter. beta 2 Receptors were observed in a more uniform distribution throughout cortical layers (including the subcortical white matter), with levels at ~35% of total beta -adrenergic receptors. In the dorsolateral prefrontal cortex, high levels of beta 1 receptors were visible in layers I, II, and VI, with low levels in layers III-V. As in the orbitofrontal cortex, beta 2 receptors were distributed uniformly throughout the dorsolateral prefrontal cortex at relatively low levels (~35% of total). No statistically significant differences were found in beta -adrenergic receptor distribution or density between AD patients and age-matched controls in either of these cortical areas, nor were differences observed between the agitated and nonagitated subgroups of AD patients. Table 3 shows the results for beta 1 receptors in the orbitofrontal cortex.

Hypothalamus

In the hypothalamus, the overall ratio of beta 1- to beta 2-adrenergic receptor binding was ~30:70. Of the areas examined, the highest levels of beta 2 binding were present in the dorsomedial and ventromedial nuclei, with intermediate levels in the lateral and posterior nuclei. Among the three patient groups, somewhat higher levels of beta -adrenergic receptors (particularly the beta 2 subtype) appeared to exist in the aggressive subgroup of AD patients and in the controls than in the nonaggressive AD subgroup (~30%). These differences, however, were not statistically significant (Table 3).

DISCUSSION

Our studies have demonstrated that abnormally low levels of cerebellar alpha 2 adrenergic receptors are restricted to a subgroup of Alzheimer's patients showing no symptoms of aggression or agitation. In the aggressive subgroup of AD patients, we found receptor levels that were at least as high as (or slightly higher than) controls, representing an ~70% increase over the nonaggressive AD subgroup. A similar, but less pronounced, increase was observed for beta -adrenergic receptors in the same aggressive AD population (vs both nonaggressive AD and control patients).

Target areas of the LC, a region known to be damaged in many AD patients, include the cerebral cortices, specific areas within the limbic system (such as thalamic and hypothalamic nuclei and the hippocampus), and the cerebellum (Cooper et al., 1991). However, many studies investigating the distribution and concentration of adrenergic receptors in these areas in the brains of AD patients have been equivocal; either no significant differences from controls are found, or the changes are small. In the majority of these studies, the AD population has not been divided into behavioral subpopulations, and the examination of specific brain areas has been conducted primarily in homogenates. For example, Meana et al. (1992) showed a reduction in the concentration of alpha 2 receptors in the AD cerebellum, frontal cortex, and hypothalamus (~30%). Kalaria et al. (1989a) also showed a decrease in alpha 2 receptors in the prefrontal cortex (~50%), but not in the cerebellum. Total beta -adrenergic receptor content showed no change in the AD prefrontal cortex, but when separate subtypes were examined, there was a slight decrease in beta 1 and a larger (~35%) increase in beta 2 receptors (Kalaria et al., 1989b). No significant changes have been reported in cerebellar beta -receptor concentration in AD. In one autoradiographic study (Vogt et al., 1991), differences in beta -receptor concentrations in the cingulate cortex between AD and control brains were found to be nonuniform. Anatomical subclasses were found within the AD group that appeared to vary in neuronal losses within the specific layers of the cingulate cortex. Certain subclasses showed no change in beta -receptor concentration, and others showed substantial increases (as much as 65%). It was speculated that clinical factors may correlate with the differences among subclasses. It is of interest that if the levels from all AD patients in our studies were averaged, only a slight decrease in cerebellar alpha 2 receptors would be evident compared with the normal elderly patient population [similar to findings by Meana et al. (1992)], and no change would be evident in cerebellar beta  receptors. Thus, our results underscore the importance of distinguishing subgroups within a disease population and a particular need for attention to behavioral symptoms that could benefit from specific treatments.

Aggression, irritability, and agitation are among the most common and problematic symptoms of Alzheimer's disease. During the course of the illness, as many as 48% of AD patients develop these behavioral symptoms, forcing them out of outpatient care settings into institutions with close supervision (Reisberg et al., 1987; Chandler and Chandler, 1988). In the normal brain, several specific cortical and subcortical regions that contain high levels of NE (Pifl et al., 1991) are thought to be associated with the modulation and control of aggression. These include the hypothalamus, amygdala/medial temporal lobe, and frontal neocortex (Weiger and Bear, 1988). Elevated NE levels have been associated with increases in aggressive behavior, and inhibitors of NE function decrease aggression. For example, agents that enhance central NE function, such as tricyclic/monoamine oxidase inhibitor antidepressants (Eichelman and Barchas, 1975) and presynaptic alpha 2 antagonists (Haller, 1995), have been shown to increase fighting in rodents. Lithium, which decreases NE availability and increases central tryptophan uptake, reduces shock-induced fighting in rodents (Eichelman et al., 1973). In humans, beta -adrenergic blockade with propranolol has been successful in managing violent behavior in neuropsychiatric syndromes (Yudofsky et al., 1981; Sorgi et al., 1986), and there is emerging clinical evidence that a subgroup of AD patients obtain significant relief from aggressive symptoms through treatment with low-dose propranolol (Weiler et al., 1988; Pauszek, 1991; Shankle et al., 1995). It has been suggested that lithium can have a clinically useful effect on impulsive aggressive behavior in humans when the behavior is not associated with psychosis (Sheard et al., 1976). Clonidine has shown promise in controlling aggression in children (Kemph et al., 1993) and adults with the neuropsychiatric syndrome autism (Koshes and Rock, 1994).

In addition to cortical and subcortical limbic regions, the cerebellum also appears to be involved in behavioral control (Schmahmann, 1991). NE fibers from the LC project via the superior cerebellar peduncle to the cerebellar cortex (Pickel et al., 1974), where the Purkinje cell appears to be the primary target. These fiber afferents make contact with tertiary or secondary Purkinje cell dendrites in the molecular layer (Bloom, 1971). In addition, NE-containing fibers are also found in the superficial region of the granule cell layer, particularly around the glomeruli, making close contact with granule cell dendrites (Kimoto et al., 1981). The axons of the Purkinje cells (after synapsing with deep cerebellar nuclei) provide the major output of the cerebellar cortex, projecting through the thalamus to the prefrontal cortex (Asanuma et al., 1983) and other association areas, such as the posterior parietal cortex (Kasdon and Jacobson, 1978) and the upper bank of the superior temporal sulcus (Yeterian and Pandya, 1989). Therefore, in addition to its well known function in the modulatory control of limb movements and other motor-associated behaviors, the cerebellar Purkinje cell output may serve in the modulation of affective and defensive/aggressive behavior, possibly by influencing circuits in the prefrontal cortex and other association areas.

Human postmortem study, particularly in an elderly patient population, can be potentially complicated by the existence of multiple medications in the patients' histories. Evidence exists that neuroleptic medication treatments can influence the levels of adrenergic receptors in mammalian brain. Because several of the patients included in this study had received neuroleptics during their history (Table 1), it is important to address the possibility that any of the observed receptor changes could have been brought about by their treatments. Of the eight patients in the aggressive subgroup, three were treated with antipsychotic medication (two with haloperidol and one with loxapine). Only one of these patients (patient 1), however, took this medication within 3 weeks of death, and neuroleptic-induced receptor concentration changes have been shown to be reversed within 7 d of stopping treatment (Wolfe et al., 1978). Several patients in our study had received antidepressant medications during their treatment, but this treatment was fairly equally distributed among the three patient groups (3/8 in the aggressive AD subgroup, 3/8 in the nonaggressive AD subgroup, and 2/7 in the elderly control group). All neuroleptic-induced adrenergic receptor changes, when present, appear to be evident in several regions throughout the brain (Greenberg, 1978; Maggi et al., 1980; Weiss and Greenberg, 1980). The changes in adrenergic receptor concentrations that we have reported were confined to the cerebellum. In summary, multiple lines of evidence suggest that the receptor concentration changes we report are not attributable to neuroleptic medication effects.

Aggression and agitation are often the factors leading to institutionalization of an individual with AD. Therefore, these symptoms account for a large part of the caregiver distress and cost involved in this disease, and it is essential to work toward understanding the neurochemical mechanisms behind these symptoms so that better treatments can be developed. Ours is among the first reports examining neurochemical lesions of specific Alzheimer's disease subgroups (based on behavioral symptoms), and the first study, to our knowledge, that has specifically investigated neurotransmitter receptor distributions/concentrations in a behavioral subgroup of dementia. A recent study examining the neuropathological correlates of agitation and physical aggression in AD revealed that AD patients with histories of unequivocal interpersonal violence had significantly greater neuron counts in the substantia nigra pars compacta than did nonviolent patients (Victoroff et al., 1996). Therefore, other evidence is appearing that important differences in monamine neurotransmitter function may exist in this aggressive subgroup of AD patients.

Our autoradiographic results raise questions about the possible mechanisms underlying the observed changes in the cerebellar cortex. Are adrenergic receptor increases in the aggressive AD subgroup a result of denervation supersensitivity, or is there a preservation of cerebellar adrenergic inputs? Studies in our laboratory have shown a relative preservation of tyrosine hydroxylase-containing neuronal fibers in the cerebellar cortex of aggressive versus nonaggressive AD patients (our unpublished data). The results reported in this paper suggest that noradrenergic inputs, which appear to decline in the normal aging cerebellum (Jones and Olpe, 1983) and diminish sharply in many AD patients, are preserved in the agitated subgroup of AD patients. We hypothesize that in the agitated AD patients presented in this autoradiographic study, inhibitory influences of NE on Purkinje cells are preserved, in the face of a cortical lesion known to be present in AD. Therefore, in the aggressive subgroup of AD, the inhibitory/modulatory output from the cerebellum is low compared with that in the nonaggressive subgroup, whereas the AD-lesioned cerebral cortex is already impaired in its ability to judge and modulate behavior, resulting in poor behavioral control. In this case, a normal level of cerebellar NE function (i.e., levels of alpha 2 adrenergic receptors that approximate normal controls), in the face of cerebral cortical impairment, can actually be abnormally high. Another question raised by our results is why the receptor changes have been observed in the cerebellum only, and not in other brain areas examined that are known to be involved in the mediation and modulation of aggression. One possibility is based on the observation that the cerebellum is one of the last brain regions to develop neuropathology and undergo degeneration in AD. In this case, it is possible that the cerebellum is the only one of these brain areas capable of maintaining/preserving noradrenergic receptors or inputs to the extent suggested.

FOOTNOTES

Received Feb. 18, 1997; revised April 25, 1997; accepted May 8, 1997.

  

This work was supported by U.S. Public Health Service Grant MH-02166. We thank Drs. Adrienne Frostholm and Andrej Rotter for valuable comments in review of this manuscript, and Toska J. Zomorodian for assistance in preparing figures and tables.

Correspondence should be addressed to Dr. Amelia Russo-Neustadt, Bio Sci II Room 1305, Institute for Brain Aging and Dementia, University of California, Irvine, CA 92697-4540.


REFERENCES

  • Asanuma C, Thach WT, Jones EG (1983) Distribution of cerebellar terminations and their relation to other afferent terminations in the ventral lateral thalamic region of the monkey. Brain Res 286:237-265[Medline].
  • Bloom FEH, Hoffer BJ, Siggins GR (1971) Studies on norepinephrine-containing afferents to Purkinje cells of art cerebellum. I. Localization of the fibers and their synapses. Brain Res 25:501-521[Web of Science][Medline].
  • Chandler JD, Chandler JE (1988) The prevalence of neuropsychiatric disorders in a nursing home population. J Geriatr Psychiatry Neurol 1:71-76.
  • Cooper JR, Bloom FE, Roth RH (1991) In: The biochemical basis of neuropharmacology, Ed 6. New York: Oxford UP.
  • Eichelman B, Barchas J (1975) Facilitated shock-induced aggression following antidepressive medication in the rat. Pharmacol Biochem Behav 3:601-604[Web of Science][Medline].
  • Eichelman B, Thoa NB, Perez-Cruet J (1973) Alkali metal cations: effects on aggression and adrenal enzymes. Pharmacol Biochem Behav 1:121-123[Medline].
  • Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198[Web of Science][Medline].
  • Greenberg LH, Weiss B (1978) Beta-adrenergic receptors in the aging rat brain: modifications induced by psychotropic drugs. In: Recent advances in the pharmacology of adrenoceptors (Szabadi E, Bradshaw CM, Bevan P, eds), pp 241-250. New York: Elsevier/North Holland Biomedical.
  • Haller J (1995) Alpha-2 adrenoceptor blockade and the response to intruder aggression in Long-Evans rats. Physiol Behav 58:101-106[Medline].
  • Ishino H, Otsuki S (1975) Frequency of Alzheimer's neurofibrillary tangles in the basal ganglia and brain-stem in Alzheimer's disease, senile dementia and the aged. Folia Psychiatr Neurol Jpn 29:279-287[Medline].
  • Jones RS, Olpe HR (1983) Altered sensitivity of forebrain neurones to iontophoretically applied noradrenaline in aging rats. Neurobiol Aging 4:97-99[Web of Science][Medline].
  • Kalaria RN, Harik SI (1989) Increased alpha 2- and beta 2-adrenergic receptors in cerebral microvessels in Alzheimer disease. Neurosci Lett 106:233-238[Web of Science][Medline].
  • Kalaria RN, Andorn AC, Harik SI (1989a) Alterations in adrenergic receptors of frontal cortex and cerebral microvessels in Alzheimer's disease and aging. Prog Clin Biol Res 317:367-374[Medline].
  • Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR (1989b) Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J Neurochem 53:1772-1781[Web of Science][Medline].
  • Kalaria RN, Stockmeier CA, Harik SI (1989c) Brain microvessels are innervated by locus ceruleus noradrenergic neurons. Neurosci Lett 97:203-208[Web of Science][Medline].
  • Kasdon DL, Jacobson S (1978) The thalamic afferents to the inferior parietal lobule of the rhesus monkey. J Comp Neurol 177:685-706[Web of Science][Medline].
  • Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL (1993) Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry 32:577-581[Web of Science][Medline].
  • Kimoto Y, Tohyama M, Satoh K, Sakumoto T, Takahashi Y, Shimizu N (1981) Fine structure of rat cerebellar noradrenaline terminals as visualized by potassium permanganate "in situ perfusion" fixation method. Neuroscience 6:47-58[Web of Science][Medline].
  • Kobayashi H, Frattola L, Ferrarese C, Spano P, Trabucchi M (1982) Characterization of beta-adrenergic receptors on human cerebral microvessels. Neurology 32:1384-1387[Abstract/Free Full Text].
  • Koshes RJ, Rock NL (1994) Use of clonidine for behavioral control in an adult patient with autism. Am J Psychiatry [Letter] 151:1714.
  • Liu Y, Jia WG, Strosberg AD, Cynader M (1992) Morphology and distribution of neurons and glial cells expressing beta-adrenergic receptors in developing kitten visual cortex. Brain Res Dev Brain Res 65:269-273[Medline].
  • Maggi A, U'Prichard DC, Enna SJ (1980) Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol 61:91-98[Web of Science][Medline].
  • Meana JJ, Barturen F, Garro MA, García-Sevilla JA, Fontán A, Zarranz JJ (1992) Decreased density of presynaptic alpha 2-adrenoceptors in postmortem brains of patients with Alzheimer's disease. J Neurochem 58:1896-1904[Web of Science][Medline].
  • Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in Alzheimer's disease. Neurology 46:130-135[Abstract/Free Full Text].
  • Mungas D, Jagust W, Reed B (1993) Neuropsychological and behavioral measures for Alzheimer's disease and other dementias. Presented at the California Alzheimer's Disease Diagnostic and Treatments Centers Strategic Planning Conference, Lake Arrowhead, CA, April.
  • Pauszek ME (1991) Propranolol for treatment of agitation in senile dementia. Indiana Med 84:16-17[Medline].
  • Pazos A, González AM, Pascual J, Meana JJ, Barturen F, García-Sevilla JA (1988) Alpha 2-adrenoceptors in human forebrain: autoradiographic visualization and biochemical parameters using the agonist [3H]UK-14304. Brain Res 475:361-365[Web of Science][Medline].
  • Pickel VM, Segal M, Bloom FE (1974) Axanol proliferation following lesions of cerebellar peduncles. A combined fluorescence microscopic and radioautographic study. J Comp Neurol 155:43-60[Web of Science][Medline].
  • Pifl C, Schingnitz G, Hornykiewicz O (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44:591-605[Web of Science][Medline].
  • Rainbow TC, Parsons B, Wolfe BB (1984) Quantitative autoradiography of beta 1- and beta 2-adrenergic receptors in rat brain. Proc Natl Acad Sci USA 81:1585-1589[Abstract/Free Full Text].
  • Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A (1987) Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry [Suppl] 48:9-15.
  • Reznikoff GA, Manaker S, Rhodes CH, Winokur A, Rainbow TC (1986) Localization and quantification of beta-adrenergic receptors in human brain. Neurology 36:1067-1073[Abstract/Free Full Text].
  • Schmahmann JD (1991) An emerging concept. The cerebellar contribution to higher function [see Comments]. Arch Neurol 48:1178-1187[Abstract/Free Full Text].
  • Shankle WR, Nielson KA, Cotman CW (1995) Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 9:233-237[Web of Science][Medline].
  • Sheard MH, Marini JL, Bridges CI, Wagner E (1976) The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 133:1409-1413[Abstract/Free Full Text].
  • Sorgi PJ, Ratey JJ, Polakoff S (1986) Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. Am J Psychiatry 143:775-776[Abstract/Free Full Text].
  • Sutin J, Shao Y (1992) Resting and reactive astrocytes express adrenergic receptors in the adult rat brain. Brain Res Bull 29:277-284[Web of Science][Medline].
  • Victoroff J, Zarow C, Mack WJ, Hsu E, Chui HC (1996) Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Arch Neurol 53:428-434[Abstract/Free Full Text].
  • Vogt BA, Crino PB, Volicer L (1991) Laminar alterations in gamma-aminobutyric acid A, muscarinic, and beta adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's disease. J Neurochem 57:282-290[Web of Science][Medline].
  • Weiger WA, Bear DM (1988) An approach to the neurology of aggression. J Psychiatr Res 22:85-98[Web of Science][Medline].
  • Weiler PG, Mungas D, Bernick C (1988) Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1:226-230.
  • Weiss B, Greenberg LH (1980) Modulation of beta-adrenergic receptors and calmodulin following acute and chronic treatment with neuroleptics. Adv Biochem Psychopharmacol 24:139-146[Medline].
  • Wolfe BB, Harden TK, Sporn JR, Molinoff PB (1978) Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther 207:446-457[Abstract/Free Full Text].
  • Yeterian EH, Pandya DN (1989) Thalamic connections of the cortex of the superior temporal sulcus in the rhesus monkey. J Comp Neurol 282:80-97[Web of Science][Medline].
  • Yudofsky S, Williams D, Gorman J (1981) Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiatry 138:218-220[Abstract/Free Full Text].
Copyright ©1997 Society for Neuroscience   0270-6474/1997/175573-08$05.00/0



This article has been cited by other articles:


Home page
 Arch NeurolHome page
N. Scarmeas, J. Brandt, D. Blacker, M. Albert, G. Hadjigeorgiou, B. Dubois, D. Devanand, L. Honig, and Y. Stern
Disruptive Behavior as a Predictor in Alzheimer Disease
Arch Neurol, December 1, 2007; 64(12): 1755 - 1761.
[Abstract] [Full Text] [PDF]

Home page
 GerontologistHome page
C. R. Kovach, Y. Taneli, P. Dohearty, A. M. Schlidt, S. Cashin, and A. L. Silva-Smith
Effect of the BACE Intervention on Agitation of People With Dementia
Gerontologist, December 1, 2004; 44(6): 797 - 806.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
N. Herrmann, K. L. Lanctot, and L. R. Khan
The Role of Norepinephrine in the Behavioral and Psychological Symptoms of Dementia
J Neuropsychiatry Clin Neurosci, August 1, 2004; 16(3): 261 - 276.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
N. Herrmann, K. L. Lanctot, G. Eryavec, and L. R. Khan
Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer's Disease Patients
J Psychopharmacol, June 1, 2004; 18(2): 215 - 220.
[Abstract] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
K. L. Lanctôt, N. Herrmann, and P. Mazzotta
Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia
J Neuropsychiatry Clin Neurosci, February 1, 2001; 13(1): 5 - 21.
[Abstract] [Full Text]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
W. C. Groves, J. Brandt, M. Steinberg, A. Warren, A. Rosenblatt, A. Baker, and C. G. Lyketsos
Vascular Dementia and Alzheimer's Disease: Is There a Difference?: A Comparison of Symptoms by Disease Duration
J Neuropsychiatry Clin Neurosci, August 1, 2000; 12(3): 305 - 315.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
C. G. Lyketsos, C. Steele, E. Galik, A. Rosenblatt, M. Steinberg, A. Warren, and J.-M. Sheppard
Physical Aggression in Dementia Patients and Its Relationship to Depression
Am J Psychiatry, January 1, 1999; 156(1): 66 - 71.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russo-Neustadt, A.
Right arrow Articles by Cotman, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russo-Neustadt, A.
Right arrow Articles by Cotman, C. W.

-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-